Cytokinetics Cash Conversion Cycle vs Free Cash Flow Per Share Analysis

CYTK Stock

USD 50.25 1.15 2.34%

Cytokinetics financial indicator trend analysis is way more than just evaluating Cytokinetics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cytokinetics is a good investment. Please check the relationship between Cytokinetics Cash Conversion Cycle and its Free Cash Flow Per Share accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytokinetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.

Cash Conversion Cycle vs Free Cash Flow Per Share

Cash Conversion Cycle vs Free Cash Flow Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cytokinetics Cash Conversion Cycle account and Free Cash Flow Per Share. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Cytokinetics' Cash Conversion Cycle and Free Cash Flow Per Share is 0.14. Overlapping area represents the amount of variation of Cash Conversion Cycle that can explain the historical movement of Free Cash Flow Per Share in the same time period over historical financial statements of Cytokinetics, assuming nothing else is changed. The correlation between historical values of Cytokinetics' Cash Conversion Cycle and Free Cash Flow Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash Conversion Cycle of Cytokinetics are associated (or correlated) with its Free Cash Flow Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Per Share has no effect on the direction of Cash Conversion Cycle i.e., Cytokinetics' Cash Conversion Cycle and Free Cash Flow Per Share go up and down completely randomly.

Correlation Coefficient

0.14

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Cash Conversion Cycle

Free Cash Flow Per Share

The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.

Most indicators from Cytokinetics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cytokinetics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytokinetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.At this time, Cytokinetics' Selling General Administrative is quite stable compared to the past year. Sales General And Administrative To Revenue is expected to rise to 24.21 this year, although Enterprise Value Multiple is projected to rise to (18.10).

	2021	2022	2023	2024 (projected)
Other Operating Expenses	256.7M	418.8M	503.7M	528.9M
Interest Expense	29.3M	51.2M	57.7M	60.6M

Other Operating Expenses Interest Expense

Cytokinetics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Net Debt	Retained Earnings	Other Assets	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Other Current Liab	Total Current Liabilities	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Short Term Investments	Other Current Assets	Property Plant And Equipment Gross
Total Assets		0.9	-0.49	0.87	-0.91	0.03	0.92	0.94	0.94	0.94	0.84	0.92	0.96	0.95	0.46	0.98	0.72	0.93	0.37	0.62	0.98	0.17	0.41	0.97	0.93	0.94
Short Long Term Debt Total	0.9		-0.8	0.99	-0.95	-0.03	0.86	0.99	0.89	0.99	0.85	0.94	0.88	0.93	0.18	0.93	0.58	0.81	0.32	0.81	0.92	-0.08	0.39	0.92	0.85	0.95
Total Stockholder Equity	-0.49	-0.8		-0.82	0.72	-0.06	-0.54	-0.76	-0.56	-0.75	-0.57	-0.68	-0.57	-0.57	0.23	-0.55	-0.3	-0.38	-0.25	-0.89	-0.55	0.4	-0.17	-0.56	-0.51	-0.64
Net Debt	0.87	0.99	-0.82		-0.92	0.01	0.81	0.97	0.85	0.97	0.8	0.91	0.84	0.91	0.12	0.91	0.49	0.78	0.35	0.79	0.88	-0.1	0.38	0.9	0.82	0.93
Retained Earnings	-0.91	-0.95	0.72	-0.92		0.09	-0.95	-0.96	-0.98	-0.96	-0.84	-0.95	-0.94	-0.89	-0.34	-0.92	-0.7	-0.81	-0.18	-0.84	-0.92	-0.02	-0.46	-0.91	-0.89	-0.92
Other Assets	0.03	-0.03	-0.06	0.01	0.09		-0.09	0.06	-0.13	0.04	-0.2	-0.13	0.13	-0.05	-0.08	-0.01	-0.13	0.03	0.86	-0.05	0.03	-0.13	-0.29	0.06	-0.1	-0.05
Common Stock Shares Outstanding	0.92	0.86	-0.54	0.81	-0.95	-0.09		0.9	0.97	0.9	0.81	0.92	0.94	0.83	0.51	0.9	0.77	0.79	0.15	0.7	0.93	0.12	0.35	0.9	0.89	0.84
Non Current Liabilities Total	0.94	0.99	-0.76	0.97	-0.96	0.06	0.9		0.92	1.0	0.85	0.94	0.94	0.94	0.24	0.95	0.65	0.85	0.38	0.81	0.95	-0.04	0.37	0.95	0.89	0.95
Other Stockholder Equity	0.94	0.89	-0.56	0.85	-0.98	-0.13	0.97	0.92		0.93	0.84	0.93	0.95	0.89	0.47	0.93	0.76	0.85	0.13	0.75	0.94	0.14	0.47	0.91	0.91	0.9
Total Liab	0.94	0.99	-0.75	0.97	-0.96	0.04	0.9	1.0	0.93		0.86	0.95	0.94	0.94	0.26	0.95	0.66	0.85	0.37	0.81	0.95	-0.03	0.37	0.94	0.9	0.96
Other Current Liab	0.84	0.85	-0.57	0.8	-0.84	-0.2	0.81	0.85	0.84	0.86		0.91	0.79	0.82	0.26	0.84	0.81	0.73	0.12	0.71	0.86	-0.06	0.29	0.82	0.73	0.84
Total Current Liabilities	0.92	0.94	-0.68	0.91	-0.95	-0.13	0.92	0.94	0.93	0.95	0.91		0.88	0.94	0.41	0.94	0.75	0.86	0.22	0.81	0.9	0.09	0.28	0.87	0.87	0.96
Other Liab	0.96	0.88	-0.57	0.84	-0.94	0.13	0.94	0.94	0.95	0.94	0.79	0.88		0.88	0.42	0.92	0.75	0.86	0.38	0.72	0.96	0.09	0.38	0.94	0.92	0.89
Property Plant And Equipment Net	0.95	0.93	-0.57	0.91	-0.89	-0.05	0.83	0.94	0.89	0.94	0.82	0.94	0.88		0.38	0.98	0.63	0.96	0.36	0.68	0.9	0.18	0.4	0.9	0.91	0.99
Current Deferred Revenue	0.46	0.18	0.23	0.12	-0.34	-0.08	0.51	0.24	0.47	0.26	0.26	0.41	0.42	0.38		0.4	0.47	0.52	0.03	0.06	0.37	0.65	-0.06	0.33	0.44	0.35
Accounts Payable	0.98	0.93	-0.55	0.91	-0.92	-0.01	0.9	0.95	0.93	0.95	0.84	0.94	0.92	0.98	0.4		0.67	0.95	0.36	0.66	0.95	0.13	0.41	0.94	0.92	0.97
Cash	0.72	0.58	-0.3	0.49	-0.7	-0.13	0.77	0.65	0.76	0.66	0.81	0.75	0.75	0.63	0.47	0.67		0.65	0.06	0.59	0.72	0.08	0.19	0.62	0.68	0.64
Non Current Assets Total	0.93	0.81	-0.38	0.78	-0.81	0.03	0.79	0.85	0.85	0.85	0.73	0.86	0.86	0.96	0.52	0.95	0.65		0.41	0.56	0.85	0.34	0.37	0.84	0.88	0.94
Non Currrent Assets Other	0.37	0.32	-0.25	0.35	-0.18	0.86	0.15	0.38	0.13	0.37	0.12	0.22	0.38	0.36	0.03	0.36	0.06	0.41		0.14	0.34	-0.03	-0.13	0.37	0.24	0.35
Long Term Debt	0.62	0.81	-0.89	0.79	-0.84	-0.05	0.7	0.81	0.75	0.81	0.71	0.81	0.72	0.68	0.06	0.66	0.59	0.56	0.14		0.64	-0.15	0.24	0.61	0.65	0.76
Cash And Short Term Investments	0.98	0.92	-0.55	0.88	-0.92	0.03	0.93	0.95	0.94	0.95	0.86	0.9	0.96	0.9	0.37	0.95	0.72	0.85	0.34	0.64		0.02	0.41	0.99	0.91	0.9
Net Receivables	0.17	-0.08	0.4	-0.1	-0.02	-0.13	0.12	-0.04	0.14	-0.03	-0.06	0.09	0.09	0.18	0.65	0.13	0.08	0.34	-0.03	-0.15	0.02		-0.01	0.01	0.15	0.14
Common Stock Total Equity	0.41	0.39	-0.17	0.38	-0.46	-0.29	0.35	0.37	0.47	0.37	0.29	0.28	0.38	0.4	-0.06	0.41	0.19	0.37	-0.13	0.24	0.41	-0.01		0.43	0.44	0.39
Short Term Investments	0.97	0.92	-0.56	0.9	-0.91	0.06	0.9	0.95	0.91	0.94	0.82	0.87	0.94	0.9	0.33	0.94	0.62	0.84	0.37	0.61	0.99	0.01	0.43		0.89	0.89
Other Current Assets	0.93	0.85	-0.51	0.82	-0.89	-0.1	0.89	0.89	0.91	0.9	0.73	0.87	0.92	0.91	0.44	0.92	0.68	0.88	0.24	0.65	0.91	0.15	0.44	0.89		0.9
Property Plant And Equipment Gross	0.94	0.95	-0.64	0.93	-0.92	-0.05	0.84	0.95	0.9	0.96	0.84	0.96	0.89	0.99	0.35	0.97	0.64	0.94	0.35	0.76	0.9	0.14	0.39	0.89	0.9

Click cells to compare fundamentals

Cytokinetics Account Relationship Matchups

Cytokinetics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	289.8M	533.8M	841.3M	1.0B	824.3M	865.5M
Short Long Term Debt Total	136.1M	138.9M	269.9M	749.3M	755.8M	793.6M
Total Stockholder Equity	(10.9M)	113.4M	243.9M	(107.9M)	(386.3M)	(367.0M)
Net Debt	99.6M	56.0M	157.3M	683.8M	642.7M	674.9M
Retained Earnings	(865.0M)	(992.3M)	(1.2B)	(1.6B)	(2.1B)	(2.0B)
Common Stock Shares Outstanding	57.6M	64.5M	76.9M	89.8M	96.5M	101.4M
Liabilities And Stockholders Equity	289.8M	533.8M	841.3M	1.0B	824.3M	865.5M
Non Current Liabilities Total	274.7M	389.2M	525.6M	1.0B	1.1B	1.2B
Other Stockholder Equity	853.3M	1.1B	1.5B	1.5B	1.7B	1.8B
Total Liab	300.8M	420.4M	597.5M	1.1B	1.2B	1.3B
Other Current Liab	1.1M	17.6M	21.0M	33.3M	35.3M	37.1M
Total Current Liabilities	26.0M	31.2M	71.9M	84.6M	102.7M	107.8M
Other Liab	143.3M	253.1M	270.5M	300.5M	345.6M	362.9M
Property Plant And Equipment Net	13.4M	22.6M	146.4M	163.2M	147.7M	155.1M
Current Deferred Revenue	12.1M	19.3M	34.4M	12.4M	14.2M	12.3M
Accounts Payable	8.2M	8.1M	21.1M	25.6M	21.5M	22.6M
Cash	36.4M	83.0M	112.7M	65.6M	113.0M	118.7M
Non Current Assets Total	56.1M	59.6M	305.6M	219.6M	196.3M	206.1M
Non Currrent Assets Other	8.9M	9.3M	7.2M	9.7M	8.0M	4.0M
Long Term Debt	45.1M	46.2M	47.4M	63.8M	607.4M	637.7M
Cash And Short Term Investments	225.1M	464.1M	471.6M	782.6M	614.8M	645.6M
Net Receivables	5.2M	4.4M	51.8M	147K	1.3M	1.2M
Common Stock Total Equity	59K	70K	84K	94K	108.1K	58.5K
Short Term Investments	188.7M	381.1M	359.0M	717.0M	501.8M	526.9M
Other Current Assets	3.5M	5.7M	12.2M	12.5M	11.9M	12.5M
Property Plant And Equipment Gross	13.4M	22.6M	146.4M	163.2M	176.1M	184.9M
Total Current Assets	233.8M	474.2M	535.7M	795.2M	628.1M	659.5M
Accumulated Other Comprehensive Income	343K	500K	679K	(869K)	(3.6M)	(10.5K)
Short Term Debt	4.6M	5.6M	29.7M	25.7M	45.9M	48.2M
Common Stock	59K	70K	84K	94K	102K	96.9K
Property Plant Equipment	4.5M	13.3M	73.3M	80.5M	92.5M	97.1M
Net Tangible Assets	(10.9M)	113.4M	243.9M	(107.9M)	(97.1M)	(92.3M)
Retained Earnings Total Equity	(865.0M)	(992.3M)	(1.2B)	(1.6B)	(1.4B)	(1.4B)
Capital Surpluse	853.3M	1.1B	1.5B	1.5B	1.7B	921.5M
Long Term Investments	42.7M	37.0M	152.1M	46.7M	40.5M	38.0M
Long Term Debt Total	45.1M	46.2M	47.4M	63.8M	73.4M	43.5M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Cytokinetics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Cytokinetics Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Cytokinetics Stock. Highlighted below are key reports to facilitate an investment decision about Cytokinetics Stock:

How To Invest In Cytokinetics

Details

Is Cytokinetics Stock a good investment?

Details

What is Cytokinetics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytokinetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.

You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(5.51)

Revenue Per Share

0.03

Quarterly Revenue Growth

0.225

Return On Assets

(0.30)

Return On Equity

(5.72)

The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytokinetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cytokinetics Cash Conversion Cycle vs Free Cash Flow Per Share Analysis

Cash Conversion Cycle vs Free Cash Flow Per Share

Cash Conversion Cycle vs Free Cash Flow Per Share Correlation Analysis

Correlation Coefficient

Cash Conversion Cycle

Free Cash Flow Per Share

Cytokinetics fundamental ratios Correlations

Cytokinetics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cytokinetics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Non Current Liabilities Total
Net Debt	+ 0.99	Short Long Term Debt Total
Non Current Liabilities Total	+ 0.99	Short Long Term Debt Total
Total Liab	+ 0.99	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net
Short Term Investments	+ 0.99	Cash And Short Term Investments

Other Stockholder Equity	- 0.98	Retained Earnings
Total Liab	- 0.96	Retained Earnings
Non Current Liabilities Total	- 0.96	Retained Earnings
Total Current Liabilities	- 0.95	Retained Earnings
Common Stock Shares Outstanding	- 0.95	Retained Earnings
Retained Earnings	- 0.95	Short Long Term Debt Total